A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials
- PMID: 37155156
- PMCID: PMC11446568
- DOI: 10.1001/jamaneurol.2023.1059
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials
Plain language summary
This Viewpoint calls for comprehensive investigations into sex differences associated with treatments in existing Alzheimer disease and integration into future Alzheimer disease and related dementia clinical trials.
Conflict of interest statement
References
-
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.. - PubMed
-
- Hohman TJ, Dumitrescu L, Barnes LL, et al. ; Alzheimer’s Disease Genetics Consortium and the Alzheimer’s Disease Neuroimaging Initiative. Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol. 2018;75(8):989–998. doi: 10.1001/jamaneurol.2018.0821 - DOI - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
